Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Dermatological Research
Published in: Archives of Dermatological Research 5/2024

01-07-2024 | Vulgar Psoriasis | RESEARCH LETTER

Evaluation of risk for hepatitis B virus reactivation in patients with psoriasis treated with biologic therapies: a single-center retrospective study

Authors: Gülsün Hazan Tabak, Neslihan Akdoğan, Sibel Doğan Günaydın, Yavuz Emre Parlar, Hatice Yasemin Balaban, Halis Şimşek

Published in: Archives of Dermatological Research | Issue 5/2024

Login to get access

Excerpt

To the editor, …
Literature
1.
Loomba R, Liang TJ (2017) Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 152(6):1297–1309CrossRefPubMed
2.
Prussick RB, Miele L (2018) Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol 179(1):16–29CrossRefPubMed
3.
Bath RK, Brar NK, Forouhar FA, Wu GY (2014) A review of methotrexate-associated hepatotoxicity. J Dig Dis 15(10):517–524CrossRefPubMed
4.
Fidan S, Capkin E, Arica DA, Durak S, Okatan IE (2021) Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-alpha therapy. Int J Rheum Dis 24(2):254–259CrossRefPubMed
5.
Caporali R, Bobbio-Pallavicini F, Atzeni F et al (2010) Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken) 62(6):749–754CrossRefPubMed
Metadata
Title
Evaluation of risk for hepatitis B virus reactivation in patients with psoriasis treated with biologic therapies: a single-center retrospective study
Authors
Gülsün Hazan Tabak
Neslihan Akdoğan
Sibel Doğan Günaydın
Yavuz Emre Parlar
Hatice Yasemin Balaban
Halis Şimşek
Publication date
01-07-2024
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 5/2024
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-024-02918-0

Other articles of this Issue 5/2024

Archives of Dermatological Research 5/2024 Go to the issue

RESEARCH LETTER

Effectiveness and safety of generic tofacitinib in alopecia areata: is the generic a cost-effective option? A retrospective study

Research Letter

Therapeutic efficacy of cell-based therapy in vitiligo: a research letter systematically reviewed using meta-analysis

REVIEW

Examining treatment strategies for xanthelasma palpebrarum: a comprehensive literature review of contemporary modalities

Original Paper

Rx -to- OTC switch increased access and lowered cost of topical adapalene

Research Letter

The relationship between spiritual practices and psychological well-being in chronic skin diseases

Research Letter

The impact of race and social vulnerability on head and neck cutaneous squamous cell carcinoma treatment and staging